LD-002

N/A

Report date: 2023/01/07 17:46:10

Base Information

Drug NameLD-002
Drug Alias NameLD-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitors
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang Blue Shield Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhejiang Blue Shield Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic NeoplasmsLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A